Literature DB >> 25919168

Estimating costs of care for meningitis infections in low- and middle-income countries.

Allison Portnoy1, Mark Jit2, Jeremy Lauer3, Adriaan Blommaert4, Sachiko Ozawa5, Meghan Stack6, Jillian Murray7, Raymond Hutubessy8.   

Abstract

Meningitis infections are often associated with high mortality and risk of sequelae. The costs of treatment and care for meningitis are a great burden on health care systems, particularly in resource-limited settings. The objective of this study is to review data on the costs of care for meningitis in low- and middle-income countries, as well as to show how results could be extrapolated to countries without sound data. We conducted a systematic review of the literature from six databases to identify studies examining the cost of care in low- and middle-income countries for all age groups with suspected, probable, or confirmed meningitis. We extracted data on treatment costs and sequelae by infectious agent and/or pathogen, where possible. Using multiple regression analysis, a relationship between hospital costs and associated determinants was investigated in order to predict costs in countries with missing data. This relationship was used to predict treatment costs for all 144 low- and middle-income countries. The methodology of conducting a systematic review, extrapolating, and setting up a standard database can be used as a tool to inform cost-effectiveness analyses in situations where cost of care data are poor. Both acute and long-term costs of meningitis could be extrapolated to countries without reliable data. Although only bacterial causes of meningitis can be vaccine-preventable, a better understanding of the treatment costs for meningitis is crucial for low- and middle-income countries to assess the cost-effectiveness of proposed interventions in their country. This cost information will be important as inputs in future cost-effectiveness studies, particularly for vaccines.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Costs; Hospital; Meningitis; Resource-limited settings

Mesh:

Year:  2015        PMID: 25919168     DOI: 10.1016/j.vaccine.2014.11.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India.

Authors:  Itamar Megiddo; Eili Klein; Ramanan Laxminarayan
Journal:  BMJ Glob Health       Date:  2018-05-09

2.  Multicenter Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacteria, Viruses, and Yeast in Cerebrospinal Fluid Specimens.

Authors:  Amy L Leber; Kathy Everhart; Joan-Miquel Balada-Llasat; Jillian Cullison; Judy Daly; Sarah Holt; Paul Lephart; Hossein Salimnia; Paul C Schreckenberger; Sharon DesJarlais; Sharon L Reed; Kimberle C Chapin; Lindsay LeBlanc; J Kristie Johnson; Nicole L Soliven; Karen C Carroll; Jo-Anne Miller; Jennifer Dien Bard; Javier Mestas; Matthew Bankowski; Tori Enomoto; Andrew C Hemmert; Kevin M Bourzac
Journal:  J Clin Microbiol       Date:  2016-06-22       Impact factor: 5.948

Review 3.  Acute bacterial meningitis in Iran: Systematic review and meta-analysis.

Authors:  Hamidreza Houri; Ali Pormohammad; Seyed Mohammad Riahi; Mohammad Javad Nasiri; Fatemeh Fallah; Hossein Dabiri; Ramin Pouriran
Journal:  PLoS One       Date:  2017-02-07       Impact factor: 3.240

4.  Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis.

Authors:  Cynthia Chen; Francisco Cervero Liceras; Stefan Flasche; Sucitro Sidharta; Joanne Yoong; Neisha Sundaram; Mark Jit
Journal:  Lancet Glob Health       Date:  2019-01       Impact factor: 26.763

5.  Etiology, clinical findings and laboratory parameters in neonates with acute bacterial meningitis.

Authors:  Hassan Boskabadi; Elahe Heidari; Maryam Zakerihamidi
Journal:  Iran J Microbiol       Date:  2020-04

6.  Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso.

Authors:  Anaïs Colombini; Caroline Trotter; Yvette Madrid; Andromachi Karachaliou; Marie-Pierre Preziosi
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

7.  Rapid Identification and Multiple Susceptibility Testing of Pathogens from Positive-Culture Sterile Body Fluids by a Combined MALDI-TOF Mass Spectrometry and Vitek Susceptibility System.

Authors:  Yueru Tian; Bing Zheng; Bei Wang; Yong Lin; Min Li
Journal:  Front Microbiol       Date:  2016-04-20       Impact factor: 5.640

8.  Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.

Authors:  Andreas Kuznik; Garba Iliyasu; Mohammed Lamorde; Mustapha Mahmud; Baba M Musa; Ibrahim Nashabaru; Stephen Obaro; Idris Mohammed; Abdulrazaq G Habib
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

9.  Hospital-based Surveillance for Pediatric Bacterial Meningitis in the Era of the 13-Valent Pneumococcal Conjugate Vaccine in Ghana.

Authors:  Lorna Awo Renner; Effua Usuf; Nuredin Ibrahim Mohammed; Daniel Ansong; Thomas Dankwah; Jonas Tettey Kusah; Sandra Kwarteng Owusu; Marah Awunyo; Bernard Arhin; Yvonne Addo; John Asamoah; Joseph Nsiari-Muzeyi Biey; Peter Slyvanus Ndow; Archibald Worwui; Madikay Senghore; Bernard Ntsama; Jason M Mwenda; Stanley K Diamenu; Brenda Kwanbana Adams; Martin Antonio
Journal:  Clin Infect Dis       Date:  2019-09-05       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.